By Mike Montemarano, Associate Editor04.21.22
The U.S. Food and Drug Administration (FDA) has issued draft guidance for dietary supplement manufacturers, distributors, and other stakeholders regarding its enforcement discretion over products containing N-acetyl-L-cysteine (NAC). FDA is accepting comments on the draft guidance by May 22.
On Mar. 31, FDA issued a joint response to two citizen petitions, from the Council for Responsible Nutrition (CRN) and the Natural Products Association (NPA), rejecting requests that the agency conclude NAC be considered a lawful dietary supplement under section 201(ff)(3)(B) of the Food, Drug, and Cosmetic Act (FD&C).
Rulemaking ‘Likely’ Pending Safety Review &
On Mar. 31, FDA issued a joint response to two citizen petitions, from the Council for Responsible Nutrition (CRN) and the Natural Products Association (NPA), rejecting requests that the agency conclude NAC be considered a lawful dietary supplement under section 201(ff)(3)(B) of the Food, Drug, and Cosmetic Act (FD&C).
Rulemaking ‘Likely’ Pending Safety Review &
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
